Agency Services & Tools

Below is a list of services and tools from our various agency partners in new product planning. 

<p class="font_8"><a href="mailto:erik.holzinger@grouph.com"><u>erik.holzinger@grouph.com</u></a></p>

groupH

groupH is an agile, commercially-focused insights and advisory firm working with clients across the pharmaceutical and biotech sectors.

Contact:

<p class="font_8"><a href="mailto:erik.holzinger@grouph.com"><u>erik.holzinger@grouph.com</u></a></p>

US Gross-to-Net Calculator

From groupH. Evidence Based, Simple, 5-min Video Introduction and Detailed Product Guide, Free-to-Use

Contact:

<p class="font_8"><a href="mailto:erik.holzinger@grouph.com"><u>erik.holzinger@grouph.com</u></a></p>

Peak Patient Share Calculator

From groupH. Evidence Based, Simple, 5-min Video Introduction and Detailed Product Guide, Free-to-Use

Contact:

<p class="font_8"><a href="mailto:andrew@headlandstrategy.com"><u>andrew@headlandstrategy.com</u></a></p>

Headland Strategy Group

Headland Strategy Group is a consultancy based in the San Francisco Bay Area that serves healthcare executives in the C-suite, Commercial, Corporate Development (BD/M&A), and R&D functions. Our clients lead some of the most innovative firms in biotechnology, pharmaceuticals, diagnostics, and medical devices. We uniquely offer a hybrid growth strategy model (spanning Commercial, BD/M&A, and R&D/Portfolio) combined with deep expertise and flexible, empathic, results-oriented service.

Contact:

<p class="font_8"><a href="mailto:test@test.com"><u>dgober@corval.io</u></a></p>

Bring Your Asset to Life

For early- to- mid-stage biopharma companies the months-long commercialization planning process is complex and daunting, requires extensive external resources, and impedes progress towards long-term success.

Corval’s intelligent, intuitive platform provides you clarity and guidance to navigate the commercialization journey and ensure you don’t miss a single step along the path to getting your treatment to patients in need.

Contact:

<p class="font_8"><a href="mailto:mailto:cbenedix@reachmr.com"><u>cbenedix@reachmr.com</u></a></p>

Actionable market insights for rare diseases

REACH is an independent pharmaceutical market research company focused on rare diseases and orphan drugs. REACH was founded in 2020 by Danielle Drayton whose years as a senior researcher and executive in the Life Sciences consulting industry led to the realization that while rare disease drug development was growing, market research solutions for rare diseases were not. REACH was founded to address a key need: high quality and timely rare disease market insights.

REACH combines decades of pharmaceutical industry and rare disease market research experience with our unique vision about the changing pharmaceutical landscape to help life sciences companies make the most informed decisions.

Contact: